Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

CEO Dekkers' legacy at Bayer? Embracing risk, à la its American rivals

Marijn Dekker's time in the Bayer CEO chair is winding down, and the Dutchman has a couple of big items left on his to-do list before he turns over the reins. But thanks to his penchant for risk-taking, in the 5-plus years he's been with the German pharma, he's gotten plenty done already.

Cipla India head Goel resigns just over a year into job

The head of Cipla's India operations has resigned from his post just more than a year after joining from GlaxoSmithKline in January last year, the company said in an email to FiercePharmaAsia.

Genentech begins search for bioinformatics chief after Gentleman leaves for 23andMe

The fight for top bioinformatics talent is heating up. With 23andMe poaching Robert Gentleman from Genentech, the Roche-owned Big Biotech now finds itself competing with the likes of Google's Calico in its hunt for a replacement.

Homeland Security names program manager for new NBAF facility in Kansas

The Department of Homeland Security has named Marty Vanier of Kansas State University as the senior program manager for strategic partnership and development for the new National Bio and Agro-Defense Facility (NBAF) expected to by completed by 2018.

Sarepta CEO Chris Garabedian resigns

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

UPDATED: Sarepta's embattled CEO steps down as DMD drug heads to the FDA

Chris Garabedian, the bullish, controversial CEO of Sarepta Therapeutics, has resigned from his post, leaving the company just as it prepares to file its Duchenne muscular dystrophy treatment for FDA approval.

Lilly execs take $3M hit to 2014 bonuses, but the pay freeze thaws for 2015

Suffering from generic competition and patent losses, Eli Lilly & Co. froze salaries and cut bonuses last year--from the top management ranks on down. But the decreases in incentive pay didn't make a huge dent in those executive pay packages.

Former Teva CEO Levin returns to biopharma as chairman of upstart Ovid Therapeutics

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

Baxter pays execs more than $8.5M to stick it out through pharma spinoff

Baxter chief Robert Parkinson--who makes a perennial appearance on the list of the top-paid helmsman in biopharma--is in prime position to return this year, despite a drop in his overall compensation. But as for his colleagues gearing up to help biopharma spinoff Baxalta break free, they're in line for some pay bumps--assuming they stick around after the split.

The $600 million man: Gilead CEO's stock gains push compensation way past estimates

Year by year, drugmakers disclose the compensation they hand out to top executives. But the year-by-year numbers don't tell the full story. As Reuters notes, CEOs have reaped payoffs much bigger than proxy filings estimate, as long-term share awards meet big stock gains.